DiaSorin (OTCMKTS:DSRLF – Get Free Report) will likely be issuing its resultson Friday, July 31st. Analysts expect the company to post earnings of $1.12 per share and revenue of $357.7870 million for the quarter.
DiaSorin Trading Up 1.3%
Shares of DSRLF stock opened at $81.00 on Thursday. DiaSorin has a 52-week low of $66.50 and a 52-week high of $100.00. The business’s fifty day moving average is $78.09 and its 200 day moving average is $76.58.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on DSRLF shares. BNP Paribas Exane lowered DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft downgraded DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, June 17th. Zacks Research raised DiaSorin to a “hold” rating in a report on Tuesday, May 12th. UBS Group lowered DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. Finally, Piper Sandler started coverage on shares of DiaSorin in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.
DiaSorin Company Profile
DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.
At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.
Featured Stories
- Five stocks we like better than DiaSorin
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
